Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 18%
Buy 18%
Hold 53%
Sell 6%
Strong Sell 6%

Bulls say

Zimmer Biomet Holdings has experienced significant growth in its product segments, notably an 11.3% increase in Technology & Data, and a 5.3% global growth in knees, demonstrating robust demand for its innovative solutions. The company's strategic focus on new product development and recent acquisitions has contributed to a healthy balance sheet and performance that aligns or exceeds industry peers. Additionally, Zimmer Biomet has set a favorable FY25 guidance, forecasting reported revenue growth of 6.7% to 7.7%, indicating confidence in sustaining momentum within the orthopedic market.

Bears say

The negative outlook on Zimmer Biomet Holdings's stock is underscored by the company's expectation of flat average selling prices (ASP) for fiscal year 2025, which, combined with modest headwinds from selling day differences, points to stagnation in revenue growth. Furthermore, the company's knee and hip product segments are experiencing growth challenges compared to peers, with weak performance particularly noted in hip sales, leading to downward revisions in operating margin estimates for the upcoming quarters. Finally, ongoing risks, including potential loss of market share, execution difficulties, and disappointing results from new product initiatives, amplify concerns about the firm’s ability to achieve favorable growth and operational performance moving forward.

ZBH has been analyzed by 17 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 18% recommend Buy, 53% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 17 analysts, ZBH has a Hold consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.